Market Cap 3.84B
Revenue (ttm) 1.53B
Net Income (ttm) 312.44M
EPS (ttm) N/A
PE Ratio 10.50
Forward PE 12.02
Profit Margin 20.37%
Debt to Equity Ratio 0.49
Volume 651,600
Avg Vol 1,539,728
Day's Range N/A - N/A
Shares Out 67.99M
Stochastic %K 52%
Beta 0.09
Analysts Strong Sell
Price Target $83.67

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 978 671 8001
Fax: 978 671 8860
Address:
201 Burlington Road, South Building, Bedford, United States
Ilya136
Ilya136 Oct. 25 at 2:05 PM
$LNTH Omg RADX RADX RADX RADX and nothing about LNTH on the fricking Lantheus board.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 23 at 1:39 PM
Lantheus has infused near $20 million past 18 months through stock purchases. asset purchases and business deals in past 18-mos. $RADX $LNTH
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 23 at 1:19 PM
Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market $IZO.CN $IZOZF $NVDA $BFLY $LNTH $RDNT https://ibn.fm/Rus4S
0 · Reply
RADX_enjoyer
RADX_enjoyer Oct. 23 at 3:02 AM
$RADX Brookline Capital Markets maintains Buy rating, reduces price target to $13 due to dilution. Brookline are happy about $LNTH increasing its stake in the company to 14.5%, a longer cash runway into 2027, and positive clinical trial updates including RAD101 (which their price target is based on)
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 22 at 8:02 PM
This last raise to me says a big player will be knocking at the door to buy Radiopharm Theranostics next year. Maybe Lantheus or Novartis. The RAD101 and RAD202 combo is a no brainer for a company serious about cancer imaging and lutetium 177… RADX ceo came from Novartis so he definitely has the connections to get it done and Lantheus now owns 14.5%.. it’s not uncommon for Lantheus investments to actually shine a light on the company to bigger pharma to spotlight acquisitions. He was COO at AAA and they acquired them for $3.9 billion. $RADX $LNTH $NVS
1 · Reply
Blizzzard
Blizzzard Oct. 22 at 2:23 PM
0 · Reply
Blizzzard
Blizzzard Oct. 21 at 7:59 PM
$LNTH pump it baby
0 · Reply
Blizzzard
Blizzzard Oct. 21 at 7:47 PM
$LNTH this stock is so good at red markets
0 · Reply
CH_Expat
CH_Expat Oct. 21 at 2:45 PM
$LNTH @RocketThief Already in or waiting for 50?
1 · Reply
Latest News on LNTH
Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:09 PM EDT - 2 months ago

Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript


Lantheus Holdings: Reassessing The Buy Thesis

Aug 6, 2025, 10:09 AM EDT - 2 months ago

Lantheus Holdings: Reassessing The Buy Thesis


Lantheus Holdings: Forget The Short Term Noise

Jul 21, 2025, 8:57 AM EDT - 3 months ago

Lantheus Holdings: Forget The Short Term Noise


Why Is Lantheus Stock Trading Lower On Wednesday?

Jul 16, 2025, 2:45 PM EDT - 3 months ago

Why Is Lantheus Stock Trading Lower On Wednesday?


Lantheus Seems Worth The (Very Real) Risks

Jul 1, 2025, 7:28 AM EDT - 4 months ago

Lantheus Seems Worth The (Very Real) Risks


Ilya136
Ilya136 Oct. 25 at 2:05 PM
$LNTH Omg RADX RADX RADX RADX and nothing about LNTH on the fricking Lantheus board.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 23 at 1:39 PM
Lantheus has infused near $20 million past 18 months through stock purchases. asset purchases and business deals in past 18-mos. $RADX $LNTH
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 23 at 1:19 PM
Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market $IZO.CN $IZOZF $NVDA $BFLY $LNTH $RDNT https://ibn.fm/Rus4S
0 · Reply
RADX_enjoyer
RADX_enjoyer Oct. 23 at 3:02 AM
$RADX Brookline Capital Markets maintains Buy rating, reduces price target to $13 due to dilution. Brookline are happy about $LNTH increasing its stake in the company to 14.5%, a longer cash runway into 2027, and positive clinical trial updates including RAD101 (which their price target is based on)
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 22 at 8:02 PM
This last raise to me says a big player will be knocking at the door to buy Radiopharm Theranostics next year. Maybe Lantheus or Novartis. The RAD101 and RAD202 combo is a no brainer for a company serious about cancer imaging and lutetium 177… RADX ceo came from Novartis so he definitely has the connections to get it done and Lantheus now owns 14.5%.. it’s not uncommon for Lantheus investments to actually shine a light on the company to bigger pharma to spotlight acquisitions. He was COO at AAA and they acquired them for $3.9 billion. $RADX $LNTH $NVS
1 · Reply
Blizzzard
Blizzzard Oct. 22 at 2:23 PM
0 · Reply
Blizzzard
Blizzzard Oct. 21 at 7:59 PM
$LNTH pump it baby
0 · Reply
Blizzzard
Blizzzard Oct. 21 at 7:47 PM
$LNTH this stock is so good at red markets
0 · Reply
CH_Expat
CH_Expat Oct. 21 at 2:45 PM
$LNTH @RocketThief Already in or waiting for 50?
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 20 at 4:44 PM
$RANI RAD101 – Brain Metastases Imaging (F18) Clinical Phase: Phase 2b - First-in-class PET agent targeting fatty acid synthase (FASN), upregulated in brain metastases. - Imaging data from 3 patients shows strong metabolic activity in suspected relapse zones. - No competitors identified; large addressable market (~300,000 cases/year in US). - Trial design includes PET/MRI concordance and longitudinal follow-up; 12/30 patients dosed. RAD202 – HER2+ Solid Tumor Therapy (Lu177) Clinical Phase: Phase 1 - Nanobody radiotherapeutic targeting HER2+ tumors refractory to Enhertu®. - Favorable safety profile in Cohort 1 (30 mCi); no SAEs observed. - Strong tumor uptake in dosimetry; Cohort 2 (75 mCi) approved. - Differentiation from existing HER2 therapies will depend on post-Enhertu positioning. $CATX $RADX $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 20 at 1:47 PM
0 · Reply
RADX_enjoyer
RADX_enjoyer Oct. 20 at 9:55 AM
$RADX ASX listing closed at an equivalent price of ~US$ 5.65. $LNTH bought US$ 5m worth of shares in today's offering (21% of the total raise) at US$ 6 per RADX share, bringing Lantheus' total holding to 14.5% of the company. US Healthcare funds have also participated in the offering via Leerink Partners (healthcare specialised investment bank) and B. Riley Securities. Positive clinical trial updates were released alongside the offering. GLTA
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 19 at 1:49 PM
$RADX $LNTH investing millions into Radiopharm Theranostics - stock resumes trading on Monday!!! $RANI
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 19 at 3:45 AM
When this deal closes $LNTH owns 15% of company and has invested $15 million. Inferring a $100,000,000 valuation of their investments. $RADX
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 18 at 5:32 PM
Lantheus (Nasdaq: $LNTH) increases stake in Radiopharm Theranostics (Nasdaq: $RADX) to 15% backing blockbuster PD-L1 and HER2 and phase 2b imaging agent their Radiotherapeutics have mult-billion dollar revenue upside. Making company a future takeover candidate similar to the multi-billion takeovers of RayzeBio and Fusion. Monday closing oversubscribed private placement Lantheus is the clear global leader in radiopharmaceuticals. $RANI
1 · Reply
RadioIsotope25
RadioIsotope25 Oct. 17 at 5:12 PM
$RADX Lantheus will own roughly 20.56% of Radiopharm Theranostics after the raise Converted to ADRs Pre-Dilution est: 958,20 shs Post Capital Raise: 1,791,541 shs All based off if they raised $24 million at $6.00 per share. $LNTH
3 · Reply
thepalace2007
thepalace2007 Oct. 16 at 5:29 PM
$LNTH $70 call option expires 11/21 lots of calls being bought following the money
0 · Reply
HappE
HappE Oct. 16 at 4:02 PM
$LNTH this ticker looooves to grab those stop losses. Does it everyday this week...
0 · Reply
TheOutsider_
TheOutsider_ Oct. 16 at 2:26 PM
$LNTH have a position here
0 · Reply
Blizzzard
Blizzzard Oct. 16 at 1:41 PM
$LNTH might want to test 60$ again
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 16 at 12:47 PM
Radiopharm Announces Strategic Co-Development Partnership + more cash from $LNTH this week… $RADX $RADX https://www.globenewswire.com/news-release/2024/12/30/3002629/0/en/Radiopharm-Announces-Strategic-Co-Development-Partnership-with-Lantheus-for-Australia.html
0 · Reply